IGM Biosciences Inc
NASDAQ:IGMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
Xinjiang International Industry Co Ltd
SZSE:000159
|
CN |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
US |
|
D
|
Dar Global PLC
LSE:DAR
|
UK |
|
Hindware Home Innovation Ltd
NSE:HINDWAREAP
|
IN |
|
B
|
Bauba Resources Ltd
JSE:BAU
|
ZA |
|
Globe Union Industrial Corp
TWSE:9934
|
TW |
|
E
|
Empyrean Energy PLC
LSE:EME
|
AU |
|
C
|
China Catalyst Holding Co Ltd
SSE:688267
|
CN |
|
Actelis Networks Inc
NASDAQ:ASNS
|
US |
|
Seadrill Ltd
OSE:SDRL
|
BM |
|
LifeTech Scientific Corp
HKEX:1302
|
CN |
|
Kye-Ryong Construction Industrial Co Ltd
KRX:013580
|
KR |
|
SFL Corporation Ltd
NYSE:SFL
|
BM |
|
A
|
Apex Healthcare Bhd
KLSE:AHEALTH
|
MY |
|
UBS Group AG
SIX:UBSG
|
CH |
|
G
|
Gdex Bhd
KLSE:GDEX
|
MY |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
US |
IGM Biosciences Inc
Other Items
IGM Biosciences Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IGM Biosciences Inc
NASDAQ:IGMS
|
Other Items
$120m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
IGM Biosciences Inc
Glance View
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
See Also
What is IGM Biosciences Inc's Other Items?
Other Items
120m
USD
Based on the financial report for Jun 30, 2025, IGM Biosciences Inc's Other Items amounts to 120m USD.
What is IGM Biosciences Inc's Other Items growth rate?
Other Items CAGR 5Y
32%
Over the last year, the Other Items growth was 159%.
